Silverarc Capital Management, LLC Mirati Therapeutics, Inc. Transaction History

Silverarc Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$27.8 - $45.35 $3.02 Million - $4.93 Million	108,787 Added 119.27%	200,000 $8.71 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $3.3 Million - $4.51 Million	91,213 New	91,213 $3.3 Million
Q3 2022 Oct 28, 2022	SELL	$59.5 - $86.7 $1.56 Million - $2.27 Million	-26,183 Reduced 71.93%	10,220 $714,000
Q2 2022 Jul 25, 2022	SELL	$39.16 - $88.71 $380,596 - $862,172	-9,719 Reduced 21.07%	36,403 $2.44 Million
Q1 2022 May 13, 2022	SELL	$75.82 - $150.97 $1.11 Million - $2.21 Million	-14,635 Reduced 24.09%	46,122 $3.79 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $1.96 Million - $2.82 Million	14,816 Added 32.25%	60,757 $8.91 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $1.08 Million - $1.45 Million	8,188 Added 21.69%	45,941 $8.13 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $4.72 Million - $5.89 Million	32,753 Added 655.06%	37,753 $6.1 Million
Q1 2021 May 18, 2021	SELL	$158.92 - $221.61 $2.38 Million - $3.32 Million	-15,000 Reduced 75.0%	5,000 $857,000
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $3.24 Million - $4.81 Million	20,000 New	20,000 $4.39 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.